Alchemab Therapeutics has appointed Ulrich Wendt, PhD MBA, as Chief Business Officer (CBO). As a proven dealmaker and strategist, Wendt brings more than a decade of experience in delivering high-value partnerships across all pipeline stages. His appointment builds on Alchemab’s recent pharma licensing deals, Series A funding extension, and progression of their first asset into clinical trials. “As CBO, Ulrich will lead Alchemab’s business development and alliance management, working ...